Antifibrotic effect of mitomycin-C on human vocal cord fibroblasts

Diána Szabó, Dávid Kovács, V. Endrész, Nóra Igaz, Kitti Jenovai, G. Spengler, L. Tiszlavicz, József Molnár, K. Burián, Mónika Kiricsi, László Rovó

Research output: Article

1 Citation (Scopus)

Abstract

Objective: Acquired laryngotracheal stenosis is a potentially life-threatening situation and a very difficult and challenging problem in laryngology. Therefore, new trends and innovative approaches based on antifibrotic drugs and minimally invasive regimens are being developed to attenuate laryngotracheal fibrosis and scarring. The purpose of this study was to examine the efficacy of mitomycin-C (MMC) to reverse the transforming growth factor (TGF)-β-induced differentiation of MRC-5 fibroblast and human primary vocal cord fibroblasts to reveal the possible applicability of MMC to laryngotracheal fibrotic conditions. Methods: Human primary fibroblast cells were isolated from vocal cord specimens of patients undergoing total laryngectomy. The established primary vocal cord fibroblast cell cultures as well as the MRC-5 human fibroblast cells were treated with 5 ng/mL TGF-β alone and then with 0.5 µg/mL MMC for 24 hours. Differentiation of fibroblasts was characterized by α-smooth muscle actin (α-SMA) immunhistochemistry, Western blot analysis, and real-time polymerase chain reaction. Cell motility was assessed by wound-healing assay. Results: Elevated α-SMA mRNA and protein expression as well as increased cell motility were observed upon TGF-β exposures. However, after MMC treatments the TGF-β-induced fibroblasts exhibited a significant decrease in α-SMA expression and wound-healing activity. Therefore, TGF-β-stimulated fibroblast-myofibroblast transformation was reversed at least in part by MMC treatment. Histopathological examinations of tissue specimens of a laryngotracheal stenosis patient supported these findings. Conclusion: Antifibrotic effects of MMC were demonstrated on the human MRC-5 cell line and on primary vocal cord fibroblast cultures. These results verify that MMC can be used with success to reverse upper airway stenosis by reverting the myofibroblast phenotype. Level of Evidence: NA Laryngoscope, 2019.

Original languageEnglish
JournalLaryngoscope
DOIs
Publication statusAccepted/In press - jan. 1 2019

Fingerprint

Vocal Cords
Mitomycin
Fibroblasts
Transforming Growth Factors
Pathologic Constriction
Myofibroblasts
Wound Healing
Cell Movement
Laryngoscopes
Laryngectomy
Otolaryngology
Cicatrix
Smooth Muscle
Actins
Real-Time Polymerase Chain Reaction
Fibrosis
Cell Culture Techniques
Western Blotting
Phenotype
Cell Line

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Antifibrotic effect of mitomycin-C on human vocal cord fibroblasts. / Szabó, Diána; Kovács, Dávid; Endrész, V.; Igaz, Nóra; Jenovai, Kitti; Spengler, G.; Tiszlavicz, L.; Molnár, József; Burián, K.; Kiricsi, Mónika; Rovó, László.

In: Laryngoscope, 01.01.2019.

Research output: Article

Szabó, Diána ; Kovács, Dávid ; Endrész, V. ; Igaz, Nóra ; Jenovai, Kitti ; Spengler, G. ; Tiszlavicz, L. ; Molnár, József ; Burián, K. ; Kiricsi, Mónika ; Rovó, László. / Antifibrotic effect of mitomycin-C on human vocal cord fibroblasts. In: Laryngoscope. 2019.
@article{24fb78005ff94b9cb2935c256ece35f2,
title = "Antifibrotic effect of mitomycin-C on human vocal cord fibroblasts",
abstract = "Objective: Acquired laryngotracheal stenosis is a potentially life-threatening situation and a very difficult and challenging problem in laryngology. Therefore, new trends and innovative approaches based on antifibrotic drugs and minimally invasive regimens are being developed to attenuate laryngotracheal fibrosis and scarring. The purpose of this study was to examine the efficacy of mitomycin-C (MMC) to reverse the transforming growth factor (TGF)-β-induced differentiation of MRC-5 fibroblast and human primary vocal cord fibroblasts to reveal the possible applicability of MMC to laryngotracheal fibrotic conditions. Methods: Human primary fibroblast cells were isolated from vocal cord specimens of patients undergoing total laryngectomy. The established primary vocal cord fibroblast cell cultures as well as the MRC-5 human fibroblast cells were treated with 5 ng/mL TGF-β alone and then with 0.5 µg/mL MMC for 24 hours. Differentiation of fibroblasts was characterized by α-smooth muscle actin (α-SMA) immunhistochemistry, Western blot analysis, and real-time polymerase chain reaction. Cell motility was assessed by wound-healing assay. Results: Elevated α-SMA mRNA and protein expression as well as increased cell motility were observed upon TGF-β exposures. However, after MMC treatments the TGF-β-induced fibroblasts exhibited a significant decrease in α-SMA expression and wound-healing activity. Therefore, TGF-β-stimulated fibroblast-myofibroblast transformation was reversed at least in part by MMC treatment. Histopathological examinations of tissue specimens of a laryngotracheal stenosis patient supported these findings. Conclusion: Antifibrotic effects of MMC were demonstrated on the human MRC-5 cell line and on primary vocal cord fibroblast cultures. These results verify that MMC can be used with success to reverse upper airway stenosis by reverting the myofibroblast phenotype. Level of Evidence: NA Laryngoscope, 2019.",
keywords = "antifibrotic effects, Laryngotracheal stenosis, mitomycin-C, primary vocal cord fibroblast, α-smooth muscle actin",
author = "Di{\'a}na Szab{\'o} and D{\'a}vid Kov{\'a}cs and V. Endr{\'e}sz and N{\'o}ra Igaz and Kitti Jenovai and G. Spengler and L. Tiszlavicz and J{\'o}zsef Moln{\'a}r and K. Buri{\'a}n and M{\'o}nika Kiricsi and L{\'a}szl{\'o} Rov{\'o}",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/lary.27657",
language = "English",
journal = "Laryngoscope",
issn = "0023-852X",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Antifibrotic effect of mitomycin-C on human vocal cord fibroblasts

AU - Szabó, Diána

AU - Kovács, Dávid

AU - Endrész, V.

AU - Igaz, Nóra

AU - Jenovai, Kitti

AU - Spengler, G.

AU - Tiszlavicz, L.

AU - Molnár, József

AU - Burián, K.

AU - Kiricsi, Mónika

AU - Rovó, László

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: Acquired laryngotracheal stenosis is a potentially life-threatening situation and a very difficult and challenging problem in laryngology. Therefore, new trends and innovative approaches based on antifibrotic drugs and minimally invasive regimens are being developed to attenuate laryngotracheal fibrosis and scarring. The purpose of this study was to examine the efficacy of mitomycin-C (MMC) to reverse the transforming growth factor (TGF)-β-induced differentiation of MRC-5 fibroblast and human primary vocal cord fibroblasts to reveal the possible applicability of MMC to laryngotracheal fibrotic conditions. Methods: Human primary fibroblast cells were isolated from vocal cord specimens of patients undergoing total laryngectomy. The established primary vocal cord fibroblast cell cultures as well as the MRC-5 human fibroblast cells were treated with 5 ng/mL TGF-β alone and then with 0.5 µg/mL MMC for 24 hours. Differentiation of fibroblasts was characterized by α-smooth muscle actin (α-SMA) immunhistochemistry, Western blot analysis, and real-time polymerase chain reaction. Cell motility was assessed by wound-healing assay. Results: Elevated α-SMA mRNA and protein expression as well as increased cell motility were observed upon TGF-β exposures. However, after MMC treatments the TGF-β-induced fibroblasts exhibited a significant decrease in α-SMA expression and wound-healing activity. Therefore, TGF-β-stimulated fibroblast-myofibroblast transformation was reversed at least in part by MMC treatment. Histopathological examinations of tissue specimens of a laryngotracheal stenosis patient supported these findings. Conclusion: Antifibrotic effects of MMC were demonstrated on the human MRC-5 cell line and on primary vocal cord fibroblast cultures. These results verify that MMC can be used with success to reverse upper airway stenosis by reverting the myofibroblast phenotype. Level of Evidence: NA Laryngoscope, 2019.

AB - Objective: Acquired laryngotracheal stenosis is a potentially life-threatening situation and a very difficult and challenging problem in laryngology. Therefore, new trends and innovative approaches based on antifibrotic drugs and minimally invasive regimens are being developed to attenuate laryngotracheal fibrosis and scarring. The purpose of this study was to examine the efficacy of mitomycin-C (MMC) to reverse the transforming growth factor (TGF)-β-induced differentiation of MRC-5 fibroblast and human primary vocal cord fibroblasts to reveal the possible applicability of MMC to laryngotracheal fibrotic conditions. Methods: Human primary fibroblast cells were isolated from vocal cord specimens of patients undergoing total laryngectomy. The established primary vocal cord fibroblast cell cultures as well as the MRC-5 human fibroblast cells were treated with 5 ng/mL TGF-β alone and then with 0.5 µg/mL MMC for 24 hours. Differentiation of fibroblasts was characterized by α-smooth muscle actin (α-SMA) immunhistochemistry, Western blot analysis, and real-time polymerase chain reaction. Cell motility was assessed by wound-healing assay. Results: Elevated α-SMA mRNA and protein expression as well as increased cell motility were observed upon TGF-β exposures. However, after MMC treatments the TGF-β-induced fibroblasts exhibited a significant decrease in α-SMA expression and wound-healing activity. Therefore, TGF-β-stimulated fibroblast-myofibroblast transformation was reversed at least in part by MMC treatment. Histopathological examinations of tissue specimens of a laryngotracheal stenosis patient supported these findings. Conclusion: Antifibrotic effects of MMC were demonstrated on the human MRC-5 cell line and on primary vocal cord fibroblast cultures. These results verify that MMC can be used with success to reverse upper airway stenosis by reverting the myofibroblast phenotype. Level of Evidence: NA Laryngoscope, 2019.

KW - antifibrotic effects

KW - Laryngotracheal stenosis

KW - mitomycin-C

KW - primary vocal cord fibroblast

KW - α-smooth muscle actin

UR - http://www.scopus.com/inward/record.url?scp=85059625405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059625405&partnerID=8YFLogxK

U2 - 10.1002/lary.27657

DO - 10.1002/lary.27657

M3 - Article

JO - Laryngoscope

JF - Laryngoscope

SN - 0023-852X

ER -